Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

16 Sept 2014

Abstract excerpt

// Carolina Simioni 1,* , Alice Cani 1,* , Alberto M. Martelli 2 , Giorgio Zauli 3 , Giovanna Tabellini 4 , James McCubrey 5 , Silvano Capitani 1,6 and Luca M. Neri 1 1 Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy 2 Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy 3 Institute for Maternal and Child Health, IRCCS “Burlo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Chronic Myeloid Leukemia Treatments
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25296981
DOI: 10.18632/oncotarget.2490

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivationPMID 25296981Read ↗

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screenSemantic proximity Read ↗

Targeting the mTOR Pathway in LeukemiaSemantic proximity Read ↗

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemiaSemantic proximity Read ↗

Outlook on PI3K/AKT/mTOR inhibition in acute leukemiaSemantic proximity Read ↗

Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and ImmunotherapySemantic proximity Read ↗

The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastomaSemantic proximity Read ↗

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathwaySemantic proximity Read ↗

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathwaysSemantic proximity Read ↗

Efficacy of dual PI-3K and mTOR inhibitors in vitro and in vivo in acute lymphoblastic leukemiaSemantic proximity Read ↗

BRD4 PROTAC Degrader ARV-825 Inhibits T-Cell Acute Lymphoblastic Leukemia by Targeting 'Undruggable' Myc-pathway GenesSemantic proximity Read ↗

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.